Maruti Suzuki Production Volume Update for January 2026

Maruti Suzuki India Limited announced its production figures for January 2026. The total passenger vehicle production reached 221,977 units, while light commercial vehicle production was 4,169 units. The total production volume, including both passenger and light commercial vehicles, amounted to 226,146 units. These figures reflect a year-over-year increase in overall production compared to January 2025.

Maruti Suzuki’s January 2026 Production Overview

Maruti Suzuki India Limited has released its production volume data for the month of January 2026. The announcement provides a detailed breakdown of vehicle production across various categories and models. Key highlights indicate positive growth trends in specific segments compared to the same period last year.

Passenger Vehicle Production Breakdown

The passenger vehicle segment witnessed a total production of 221,977 units in January 2026. This figure encompasses various sub-segments, including mini, compact, utility vehicles, and vans. Here’s a more granular look:

  • Mini (Alto, S-Presso): 19,976 units
  • Compact (Baleno, Celerio, Dzire, Ignis, Swift, WagonR, OEM Model): 88,968 units
  • Utility Vehicles (Brezza, Ertiga, e Vitara, Fronx, Jimny, Victoris, XL6, OEM Models): 99,856 units
  • Vans (Eeco): 13,177 units

Notably, the combined production of Mini and Compact sub-segments totaled 108,944 units.

Light Commercial Vehicle Production

In addition to passenger vehicles, Maruti Suzuki also produced 4,169 units of light commercial vehicles (Super Carry) during January 2026.

Total Production Volume

The grand total production for January 2026, encompassing both passenger and light commercial vehicles, reached 226,146 units. This represents a significant increase compared to the 206,851 units produced in January 2025, indicating a strong performance in production output year-over-year.

Source: BSE

Previous Article

Thyrocare Q3 FY26 Earnings Call Transcript Highlights Strong Growth and Future Strategies

Next Article

J.B. Chemicals & Pharmaceuticals Board to Consider Interim Dividend